Vemurafenib Promising Against Deadly Melanoma

February 23, 2012

ABC News

Lynn Schuchter, MD, chief of the division of Hematology-Oncology, is quoted in an story about the latest results of a trial of the targeted drug vemurafenib, which was approved for the treatment of metastatic melanoma last year. "I've treated patients [with melanoma] for almost 25 years and never seen a drug with this kind of activity," said Schuchter, an author of the study, which was published this week in the New England Journal of Medicine. "It's so much better than the therapies that have been available to us before." Trial patients on the drug lived, on average, for an additional 15.9 months after treatment began, compared with the six to 10 months typically seen with the disease. The new study provides longer follow-up -- more than a year after patients began treatment – to results published last year. "[They] really show much prolonged survival," Schuchter said, "and that's been my experience clinically as well, that they're living longer and with high quality of life." Read More